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INTRODUCTION
The prevalence of allergic diseases, such as asthma, allergic 
rhinitis, and atopic dermatitis, is soaring worldwide. However, 
allergic diseases exhibit predilection in prevalence according to 
age, sex and ethnicity.1 This difference in prevalence is associat-
ed with genetic predisposition as well as regional and cultural 
factors. Culprit allergens and allergenic sensitization patterns 
are also related these factors.2
Confirmation of culprit allergens in an individual patient is 
crucial for the diagnosis of allergic diseases. Proving the pres-
ence of allergen-specific immunoglobulin E (sIgE) in the serum 
can be used as a surrogate method to detect and identify the 
culprit allergen.3 The in vivo skin prick test (SPT) is a popular 
one used worldwide to identify the culprit allergen. However, 
this test has some limitations in clinical settings. For example, 
the results can be affected by anti-histamine use; therefore, SPT 
cannot be used to test allergic patients who cannot cease this 
medication. As an alternative to the SPT, in vitro assays have 
been developed for clinical use. The radioallergosorbent test 
was first introduced for the detection of IgE.4 Many commer-
cially available immunochemical assays based on enzyme im-
munoassay (EIA) or fluorescent enzyme immunoassay (FEIA) 
are now widely used in clinical settings.5
Among these assays, the ImmunoCAP® test based on the 
FEIA technique is one of the most popular singlet methods for 
the detection of sIgE for individual allergens.6 However, the test-
cost and elapse-time of this method are relatively higher than 
those of multiplex tests. Recently, several multiplex allergen-
screening tests have been developed for clinical use. However, 
these systems have several limitations, such as long assay time, 
and modest sensitivity and specificity.5,7,8 Moreover, multiplex 
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allergen screening panels need to be modified according to 
geographical regions and ethnical differences in culprit aller-
gens. To address this issue, manufactures have to design certain 
panels to identify culprit allergens related to specific allergic 
diseases.
One of the limitations of the multiplex assays is the low detec-
tion rate for specific allergens included in panels designed for 
disease-specific or region-specific use. Therefore, adding new 
allergens does not guarantee the superiority of the determina-
tion of culprit allergens.9 A recently developed multiplex sIgE 
test, Allergy-Q®, can detect 43 allergen sIgEs simultaneously. 
This assay is based on the EIA technique using nitrocellulose 
membrane as the solid-phase for allergen immobilization. The 
system has an internal calibration setup that enables the user to 
adjust the concentration of sIgE in relation to measured total 
IgE level in patients’ sera quantitatively. In this study, we com-
pared the sIgE detection performance of Allergy-Q® EIA panel 
with that of ImmunoCAP® FEIA in 260 Korean patients with 
known allergies for 16 individual allergens, including important 
inhalant, food, and microorganism allergens in Korea. 
MATERIALS AND METHODS
Study participants
Between January and June of 2011, patients who visited the 
Allergy and Asthma Clinic at Severance Hospital, Yonsei Uni-
versity Health System for the diagnosis of their allergic diseases 
were enrolled in our study, according to the clinical diagnosis 
based on their medical history (asthma, allergic rhinitis, atopic 
dermatitis, and food allergy). All the patients took allergen sIgE 
ImmunoCAP® tests for suspected culprit allergens. Additional 
sera sampling for Allergy-Q® assay was performed. Informed 
consent was obtained from all patients and/or their guardians. 
The Institutional Review Board of the Yonsei University College 
of Medicine approved this study (IRB no. 1-2013-0039). 
Inclusion criteria were as follows: age, 1–75 years; clinically di-
agnosed with IgE-related allergic diseases to inhalant and/or 
food allergens; and absence of other chronic comorbid diseas-
es, including autoimmunity, malignancy, chronic infection, or 
other immune-related diseases.
Serum preparation and allergen selection
Five milliliters of the whole blood was collected in a vacuum 
tube (Vacuette®; Greiner Bio-One GmbH, Kremsmünster, Aus-
tria) for serum separation. Serum was separated by centrifuga-
tion at 3,000 rpm for 5 minutes, aliquoted into several round-
bottom tubes (5-mL BD FalconTM tubes; BD Bioscience Discov-
ery Labware, Bedford, MA, USA), and frozen at -80°C for long-
term storage or until further use.
Sixteen dominant allergens were selected for inter-assay com-
parison between Allergy-Q® EIA and ImmunoCAP® FEIA. Sev-
en inhalant allergens (Dermatophagoides pteronyssinus, D. fari-
nae, cat dander, dog dander, birch, mugwort, and timothy pol-
len), 5 food allergens (egg white, cow’s milk, wheat, shrimp, and 
peanut) and 4 microorganism allergens (Alternaria alternata, 
Candida albicans, staphylococcal enterotoxin B, and Tricho-
phyton rubrum) were included. These allergens were selected 
according to their clinical importance and prevalence in Ko-
rea.10-13
In vitro allergen sIgE measurements
Serum aliquots were sent to the laboratory without any patient 
identification. We performed allergen sIgE detection using 2 dif-
ferent systems simultaneously (PROTIATM Allergy-Q®; Proteom-
etech, Seoul, Korea and ImmunoCAP® 250; Phadia, Uppsala, 
Sweden). Both the Allergy-Q® EIA and ImmunoCAP® FEIA sys-
tems were operated according to the manufacturers’ instruc-
tions. The sIgE detection range of Allergy-Q® EIA was 0.15-100 
kU/L and that of ImmunoCAP® FEIA was 0.1-100 kU/L. Howev-
er, the classified sIgE scales of the 2 systems were identical (class 
0: under 0.35 kU/L, class 1: 0.35-0.7 kU/L, class 2: 0.7-3.5 kU/L, 
class 3: 3.5-17.5 kU/L, class 4: 17.5-50 kU/L, class 5: 50-100 kU/L, 
and class 6: >100 kU/L).
Statistical analysis
We analyzed the correlation of sIgE concentrations measured 
by the 2 methods using intra-class correlation analysis. To com-
pare the equivalence of the 2 methods, we used Passing-Bablok 
(PB) regression analysis.14 Class association was evaluated by 
gamma analysis. Agreement of detection was evaluated by Co-
hen’s kappa analysis. We assessed and categorized the kappa 
value as almost perfect (0.8-1.0), substantial (0.6-0.8), moderate 
(0.4-0.6), fair (0.2-0.4), and poor (below 0.2).15 We calculated 3 
agreement percentages (positive, negative, and total agree-
ment). The positive and negative agreement percentages were 
calculated with the proportions of agreement for the average of 
their positive and negative responses. The total agreement per-
centage was calculated following the same methodology used 
in a previous study: (total number of results-number of discrep-
ancies) ×100/total number of results.8 A P value of <0.05 was 
considered statistically significant. For the statistical analysis, 
we used MedCalc 11.0 (MedCalc Software, Belgium) and SPSS 
12.0 (SPSS Inc., Chicago, IL, USA) statistical software.
 
RESULTS
Characteristics of study participants and paired result sets
Two-hundred and sixty patients (median age, 11 years [range, 
1–71 years]; 151 males and 109 females) were enrolled in this 
study. Table 1 lists their demographic characteristics according 
to allergic disease. Overall, 1,799 Allergy-Q®-ImmunoCAP®-
matched result sets were obtained and analyzed. The final num-
bers of matched result sets for each allergen are listed in Table 2.
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Inter-method comparison of sIgE concentrations
The correlation patterns and intra-class correlation coeffi-
cients (ICCs) of each allergen sIgE are presented in Figs. 1, 2, 
and 3. Almost all the allergen sIgE concentrations showed ICCs 
above 0.5, except for mugwort pollen and A. alternata sIgEs 
(Table 3). 
Passing-Bablok regression analysis revealed that cat dander 
and peanut allergen sIgE measurements of Allergy-Q® were 
most similar to those of ImmunoCAP® FEIA (cat dander: inter-
cept, 0.089 [95% confidence interval {CI} 0.070, 0.100] and 
slope, 1.112 [95% CI 0.878, 1.478]; peanut: intercept, 0.027 [95% 
CI 0.008, 0.039] and slope, 1.021 [95% CI 0.897, 1.314]). Some of 
Table 1. Demographic characteristics of the study patients
No. of patients (%) Male:female Age, year median [1Q, 3Q] (range)
Total 260 (100.0) 151:109 (1:0.72) 11.0 [3, 27.75] (1-71)
Asthma 69 (26.5) 37:32 (1:0.86) 14.0 [5.5, 36] (2-61)
Allergic rhinitis 110 (42.3) 55:55 (1:1) 23.5 [10, 36] (1-72)
Atopic dermatitis 176 (67.7) 106:70 (1:0.66) 6.0 [2, 21] (1-45)
Food allergy 47 (18.1) 33:14 (1:0.42) 3.0 [2, 5] (1-37)
Table 2. Tested allergens and number of matched set results
Allergens (matched set results, n)
Aeroallergens Food allergens Microorganism allergen
Dermatophagoides pteronyssinus (79) Egg white (180) Alternaria alternata (72)
Dermatophagoides farinae (233) Cow’s milk (172) Candida albicans (90)
Cat dander (74) Wheat (151) Staphylococcal enterotoxin B (87)
Dog dander (73) Peanut (163) Trichophyton rubrum (89)
Birch pollen (82) Shrimp (110)  
Mugwort pollen (72)   
Timothy pollen (72)   
Table 3. Correlation, equality measurement and association analysis between Allergy-Q® and ImmunoCAP® assays
Allergen
Intermethod comparison Association of class
ICC [95% CI] PB Intercept [95% CI] PB Slope [ 95% CI] Gamma P value
D. pteronyssinus 0.621 (0.464, 0.740) 0.096 (0.016, 0.148) 0.456 (0.338, 0.696) 0.858 <0.0001
D. farinae 0.621 (0.535, 0.694) 0.095 (0.089, 0.098) 0.231 (0.181, 0.273) 0.889 <0.0001
Cat dander 0.847 (0.768, 0.901) 0.089 (0.070, 0.100) 1.112 (0.878, 1.478) 0.916 <0.0001
Dog dander 0.932 (0.893, 0.957) 0.090 (0.065, 0.109) 0.752 (0.627, 1.000) 0.957 <0.0001
Birch pollen 0.922 (0.881, 0.949) 0.091 (0.078, 0.097) 0.434 (0.346, 0.722) 0.916 <0.0001
Mugwort pollen 0.280 (0.053, 0.479) 0.115 (0.078, 0.175) 1.639 (1.121, 2.158) 0.914 <0.0001
Timothy pollen 0.893 (0.834, 0.932) -0.021 (-0.062, 0.009) 2.119 (1.017, 3.086) 0.951 <0.0001
Egg white 0.751 (0.679, 0.808) -0.012 (-0.037, 0.043) 0.640 (0.450, 0.926) 0.918 <0.0001
Cow’s milk 0.773 (0.706, 0.827) 0.077 (0.065, 0.085) 0.383 (0.303, 0.576) 0.925 <0.0001
Wheat 0.613 (0.503, 0.703) 0.035 (0.020, 0.058) 0.868 (0.604, 1.001) 0.933 <0.0001
Peanut 0.928 (0.903, 0.947) 0.027 (0.008, 0.039) 1.021 (0.897, 1.314) 0.936 <0.0001
Shrimp 0.688 (0.575, 0.775) 0.099 (0.095, 0.100) 0.052 (0.000, 0.171) 0.907 <0.0001
A. alternata 0.490 (0.293, 0.647) 0.076 (0.050, 0.090) 0.792 (0.519, 1.683) 0.949 <0.0001
C. albicans 0.579 (0.424, 0.701) 0.095 (0.091, 0.100) 0.246 (0.000, 0.443) 0.987 <0.0001
S. enterotoxin B 0.968 (0.952, 0.979) 0.087 (0.066, 0.090) 1.256 (0.979, 1.723) 0.961 <0.0001
T. rubrum 0.968 (0.952, 0.979) 0.082 (0.073, 0.085) 0.876 (0.744, 1.361) 0.983 <0.0001
D. pteronyssinus, Dermatophagoides pteronyssinus; D. farina, Dermatophagoides farina; A. alternate, Alternaria alternate; C. albicans, Candida albicans; S. entero-
toxin B, staphylococcal enterotoxin B; T. rubrum, Trichophyton rubrum.
ICC, Intraclass coefficient; PB, Passing-Barblok analysis. 
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the allergen sIgE results showed multiple differences (slope: 
0.456 for D. pteronyssinus; 0.231 for D. farinae; 0.434 for birch 
pollen; and 2.119 for timothy pollen), (Table 3). 
Association analysis in categorical classes
By applying class boundaries, the concordance of the 2 meth-
ods was stratified into classes 0-6. The results of the gamma 
analysis indicated that almost all the tested allergen sIgEs re-
sults had strong associations with their classes (gamma >0.9). 
Although the gamma values of D. pteronyssinus and D. farinae 
sIgEs were below 0.9, they exhibited good associations with 
their classes (gamma >0.8; Table 3).
Agreement analysis of qualitative results
We considered 0.35 kU/L as the cutoff value for positive re-
sults in each assay in accordance with the manufacturers’ 
guidelines. We calculated the positive, negative, and total agree-
ment percentages, and the kappa values between the 2 meth-
ods for each allergen sIgE detection assay (Table 4). For almost 
all the allergen sIgEs, we observed 86.63%-96.63% total agree-
ment (83.62%-97.87% positive and 83.87%-92.11% negative 
agreement). In the kappa analysis, almost all the allergen sIgE 
results exhibited almost perfect (9 allergens) or substantial (7 
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Fig. 1. Scattered plots of inhalant allergen 
sIgE concentrations, as measured by the Im-
munoCAP® assay (x-axis) and the Allergy-Q® 
assay (y-axis). Each line in the plot represents 
the class cut-off of each assay (class 0: 
<0.35, class 1: 0.35-0.7, class 2: 0.7-3.5, 
class 3: 3.5-17.5, class 4: 17.5-50, class 5: 50-
100, class 6: >100 kU/L). Shaded boxes rep-
resent concordant areas in each concentra-
tion class. Each plot represents an inhalant 
allergen: Dermatophagoides pteronyssinus 
(A), D. farinae (B), cat dander (C), dog dander 
(D), birch pollen (E), mugwort pollen (F), and 
timothy pollen (G). 
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Fig. 2. Scattered plots of food allergen sIgE 
concentrations, as measured by the Immuno-
CAP® assay (x-axis) and the Allergy-Q® assay 
(y-axis). Each line in the plot represents class 
cut-off of each assay (class 0: <0.35, class 1: 
0.35-0.7, class 2: 0.7-3.5, class 3: 3.5-17.5, 
class 4: 17.5-50, class 5: 50-100, class 6: 
>100 kU/L). Shaded boxes represent concor-
dant areas in each concentration class. Each 
plot represents a food allergen: egg white (A), 
cow’s milk (B), wheat (C), peanut (D), and 
shrimp (E).
Fig. 3. Scattered plots of food microorganism 
sIgE concentrations, as measured by the Im-
munoCAP® assay (x-axis) and the Allergy-Q® 
assay (y-axis). Each line in the plot represents 
class cut-off of each assay (class 0: <0.35, 
class 1: 0.35-0.7, class 2: 0.7-3.5, class 3: 3.5-
17.5, class 4: 17.5-50, class 5: 50-100, class 
6: >100 kU/L). Shaded boxes represent con-
cordant areas in each concentration class. 
Each plot represents a microorganism aller-
gen: Alernaria alternata (A), Candida albicans 
(B), staphylococcal enterotoxin B (C), and 
Trichophyton rubrum (D). 
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Table 4. Agreement analysis between Allergy-Q® and ImmunoCAP® systems
Allergen
Agreement % Kappa analysis
Positive % Negative % Total % (agree/total) κ P value
D. pteronyssinus 87.10 91.67 89.87 (71/79) 0.788 <0.0001
D. farina 83.62 89.97 87.55 (204/233) 0.737 <0.0001
Cat dander 92.13 88.14 90.54 (67/74) 0.803 <0.0001
Dog dander 91.43 92.11 91.78 (67/73) 0.836 <0.0001
Birch pollen 90.00 90.48 90.24 (74/82) 0.805 <0.0001
Mugwort pollen 93.48 88.46 91.67 (66/72) 0.820 <0.0001
Timothy pollen 93.33 88.89 91.67 (66/72) 0.824 <0.0001
Egg white 89.27 89.62 89.44 (161/180) 0.790 <0.0001
Cow’s milk 88.08 84.77 86.63 (149/172) 0.729 <0.0001
Wheat 91.76 89.39 90.73 (137/151) 0.812 <0.0001
Peanut 89.77 88.00 88.96 (145/163) 0.778 <0.0001
Shrimp 92.68 78.57 89.09 (98/110) 0.713 <0.0001
A. alternate 95.58 83.87 93.06 (67/72) 0.795 <0.0001
C. albicans 96.30 88.89 94.44 (85/90) 0.852 <0.0001
S. enterotoxin B 97.18 87.50 95.40 (83/87) 0.847 <0.0001
T. rubrum 97.87 91.89 96.63 (86/89) 0.898 <0.0001
Abbreviations as in Table 3.
DISCUSSION
The Allergy-Q® EIA system is a recently developed multiplex 
sIgE detection assay. The characteristics of this assay are inter-
nal calibration using 5 standard IgE level measurements and 
decreased sample requirement compared to multiplex assays. 
In this study, we performed an inter-assay comparison be-
tween the Allergy-Q® EIA system and the ImmunoCAP® FEIA 
system, a well-known established singleplex sIgE detection as-
say. We collected clinical data based on Korean ethnicity.
Serum sIgE assays provide 2 kinds of results to clinicians, 
qualitative information (0-6 classes) and quantitative measure-
ments in SI units (kU/L). The former is more important in the 
case of drug or occupational allergens, where sIgE levels are 
low, although they are important culprits in specific patients.16,17 
In these cases, sensitivity is important. In other cases, concen-
tration measurements of sIgE have to be accurate. For example, 
several food sIgE levels are used as clinical surrogates for the 
oral food challenge test to diagnose food allergy in childhood, 
such as allergies to egg, milk, and peanut.18
In our study, Allergy-Q® EIA exhibited good agreement ratio 
(>85% for all tested allergens) and high kappa values (>0.7 for 
all tested allergens), when compared toImmunoCAP® FEIA, 
suggesting that Allergy-Q® may be used for the quantitative 
measurement for sIgE. Moreover, Allergy-Q® EIA exhibited a 
good correlation with ImmunoCAP® FEIA for many tested al-
lergens (>0.7 ICC for 9 allergens). In particular, the peanut sIgE 
level obtained using Allergy-Q® EIA showed a very good corre-
lation with that obtained using ImmunoCAP® FEIA (ICC 0.928, 
PB slope 1.021). Because the ICC was high, the PB slope and in-
tercept were close to one and zero, respectively; therefore, the 2 
assays were considered almost identical. Moreover, Allergy-Q® 
EIA can be used as an alternative method to estimate the con-
centration of peanut sIgE for the diagnosis of clinical or symp-
tomatic peanut allergy. However, egg white and cow’s milk sIgE 
levels exhibited fair ICC values, but their PB slope was lower 
than 1, indicating that the sIgE level measured by Allergy-Q® 
was slightly lower than that measured by ImmunoCAP®. 
These discrepancies between the 2 methods may have been 
attributed to differences in the technique and development of 
these assays. Both the Allergy-Q® and ImmunoCAP® assays use 
the same principle to detect sIgE: the indirect immunoassay 
technique using an allergen-absorbed solid phase. Moreover, 
an anti-human IgE-conjugated enzyme is used to develop the 
detecting signal. However, the 2 assay systems use different 
substrate-enzyme amplification systems (ImmunoCAP®: galac-
tosidase and fluorescent substrate; Allergy-Q®: alkaline phos-
phatase and visible substrate).6 Moreover, in the Allergy-Q® as-
say system, the IgE reactivity of an allergen on the nitrocellulose 
membrane can be affected by adjacent allergens. 
Furthermore, the quality of used allergens might affect perfor-
mance. Although the same species of plants and mites were 
used in the 2 assays, the cultivating conditions, including feed-
ing material, temperature, humidity, geographical locations, 
and genetic polymorphism might be different, and these fac-
tors might affect the results.19,20 The extraction technique and 
quality control of manufacturing of allergens might also affect 
the results.21
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Although the Allergy-Q® EIA system exhibited some discor-
dance with ImmunoCAP® FEIA, there are several clinical ad-
vantages in Allergy-Q®. This method can provide exact IgE lev-
els in international units (kU/L), in accordance with the WHO 
international Reference Preparation 75/502 for Human IgE.22 
Quantitative measurement of sIgE can help clinicians select 
culprit allergens that need to be included or discarded in aller-
gen-specific immunotherapy and avoidance strategy.23,24 More-
over, this enables monitoring changes in sIgE levels in child-
hood food allergy patients during clinical course.18
The advantages of the multiplex allergen sIgE detection kits 
are short running time, small amount of blood sample, and 
more clinical information about culprit allergens. For clinical 
relevance, false positivity and false negativity must be mini-
mized.25 In this study, despite minimum requirement for serum 
volume, the Allergy-Q® system showed a high agreement per-
centage with the ImmunoCAP® system for most of the allergens 
tested, suggesting that it could be an alternative method for al-
lergy diagnosis.
We did not compare the assay results with skin tests in this 
study. Using well-standardized allergenic extracts, it had been 
known that the concordance rate of SPT and serum sIgE mea-
surement ranged from 85% to 95%.26 Furthermore, differences 
in the condition of the allergens used in vivo or in vitro, includ-
ing preparation, manufacturer, and storage conditions, can 
strongly affect the results. Thus, we concluded that SPT might 
not be an appropriate surrogate to analyze our results from the 
2 different in vitro assays.
In conclusion, the Allergy-Q® EIA assay showed good sIgE de-
tection performance compared to ImmunoCAP® FEIA for most 
of the allergens tested. However, careful clinical analysis will be 
required for several allergens for quantitative use. Moreover, we 
tested this system only in Koreans dwelling in the mid-latitude 
northern hemisphere. Careful consideration is required when 
applying our data to other ethnic or regional populations.
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